Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris. The trial was conducted ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris. The trial was conducted by ...

The National Health Commission, in collaboration with several other authorities, has jointly released a directive aimed at strengthening the management of pharmaceutical purchases and sales, as ...

- Acne Products Market- Baby Acne Medicine Market- The global Oral Acne Medicine market was valued at USD 929.9 Million in 2023 and is anticipated to reach USD 1144.1 Million by 2030, witnessing a ...

EU China Trade Relations: The EU has taken significant action by excluding Chinese companies from selling medical devices in response to Beijing's restrictions on European imports. This first-ever ...

The reported action under the EU's IPI regulation means Chinese companies could face a 5-year 'freeze out' in participating in EU public tenders for medical device-related contracts. Image credit ...

The 2025 Formula E race is currently underway this weekend at the Shanghai International Circuit in the city‘’s Jiading district. Prior to the race, Formula E staff members visited the ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced drug can hold its own against FDA-approved products like Seysara and ...

The European Union agreed overwhelmingly to curb Chinese medical device manufacturers’ access to public procurement contracts in the bloc, according to people familiar with the matter.

Beijing criticized as protectionist the European Union’s plan to curb Chinese medical device manufacturers’ access to public procurement ... China urged the EU to handle any differences ...

The Chinese Phase III study (NCT06192264), which was conducted by Ascletis, saw denifanstat achieve a 33.2% treatment success in patients with acne vulgaris taking the oral medication for 12 weeks.